Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mast Cell Disorders
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Related Questions
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
What is the overlap of POTS and Ehlers-Danlos with MCAS?
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell activation syndrome besides omalizumab?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
Do you use AIT as an adjunct therapy in addition to nasal sprays and oral medications for CRS?
Is omalizumab an option for a patient needing a specific antibiotic with an IgE-mediated reaction who continues to have reactions during a desensitization?
Any thoughts on whether oral immunotherapy versus Xolair would provide a better chance of outgrowing a food allergy?
How do you reassure families that no allergy testing is needed for urticaria?
